CN108939076A - 用于治疗腹泻的产品和方法 - Google Patents

用于治疗腹泻的产品和方法 Download PDF

Info

Publication number
CN108939076A
CN108939076A CN201810755897.7A CN201810755897A CN108939076A CN 108939076 A CN108939076 A CN 108939076A CN 201810755897 A CN201810755897 A CN 201810755897A CN 108939076 A CN108939076 A CN 108939076A
Authority
CN
China
Prior art keywords
receptor antagonist
patient
diarrhea
bisfentidine
cetirizine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810755897.7A
Other languages
English (en)
Chinese (zh)
Inventor
R.B.霍根二世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MAREGADE RX LLC
Original Assignee
MAREGADE RX LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MAREGADE RX LLC filed Critical MAREGADE RX LLC
Publication of CN108939076A publication Critical patent/CN108939076A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201810755897.7A 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法 Pending CN108939076A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782608P 2013-03-14 2013-03-14
US61/782,608 2013-03-14
CN201480022471.0A CN105324112B (zh) 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480022471.0A Division CN105324112B (zh) 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法

Publications (1)

Publication Number Publication Date
CN108939076A true CN108939076A (zh) 2018-12-07

Family

ID=50680150

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810755897.7A Pending CN108939076A (zh) 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法
CN201480022471.0A Active CN105324112B (zh) 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480022471.0A Active CN105324112B (zh) 2013-03-14 2014-03-14 用于治疗腹泻的产品和方法

Country Status (20)

Country Link
US (4) US9717726B2 (cg-RX-API-DMAC7.html)
EP (3) EP3269364B1 (cg-RX-API-DMAC7.html)
JP (4) JP6313417B2 (cg-RX-API-DMAC7.html)
KR (4) KR20180088514A (cg-RX-API-DMAC7.html)
CN (2) CN108939076A (cg-RX-API-DMAC7.html)
AU (3) AU2014239878B2 (cg-RX-API-DMAC7.html)
BR (2) BR122017004716A2 (cg-RX-API-DMAC7.html)
CA (1) CA2906005C (cg-RX-API-DMAC7.html)
DK (1) DK2968205T3 (cg-RX-API-DMAC7.html)
ES (2) ES2655505T3 (cg-RX-API-DMAC7.html)
HK (1) HK1247557B (cg-RX-API-DMAC7.html)
HU (1) HUE035201T2 (cg-RX-API-DMAC7.html)
IL (3) IL273377B2 (cg-RX-API-DMAC7.html)
MX (2) MX366329B (cg-RX-API-DMAC7.html)
MY (1) MY175326A (cg-RX-API-DMAC7.html)
PL (1) PL2968205T3 (cg-RX-API-DMAC7.html)
PT (1) PT2968205T (cg-RX-API-DMAC7.html)
RU (1) RU2015143475A (cg-RX-API-DMAC7.html)
WO (1) WO2014152420A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201708539B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
US20180185356A1 (en) * 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi
CN112616320B (zh) * 2019-08-05 2024-04-05 株式会社日立高新技术 等离子处理装置
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN117280446A (zh) 2021-08-23 2023-12-22 株式会社日立高新技术 等离子处理装置以及等离子处理方法
WO2023049205A1 (en) 2021-09-22 2023-03-30 Hista Rx Llc Compositions and methods for treating and preventing interstitial cystitis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101299996A (zh) * 2005-09-30 2008-11-05 麦克内尔-Ppc股份有限公司 含有唾液诱生剂的口服组合物
US20090312358A1 (en) * 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5096894A (en) * 1990-04-03 1992-03-17 Bristol-Myers Squibb Company Rice dextrin oral rehydration solution
AU7255094A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-antihistamine combinations
US6264984B1 (en) * 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2430292A1 (en) 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
WO2003044023A1 (en) * 2001-11-23 2003-05-30 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
SE528789C2 (sv) 2004-09-10 2007-02-13 Sandvik Intellectual Property PVD-belagt skär av hårdmetall samt sätt att tillverka detta
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US8207292B2 (en) 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
CA2721133C (en) * 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101299996A (zh) * 2005-09-30 2008-11-05 麦克内尔-Ppc股份有限公司 含有唾液诱生剂的口服组合物
US20090312358A1 (en) * 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ANDREAS ALY ET AL.: "Effect of an H2-Receptor Blocking Agent on Diarrhoeas after Extensive Small Bowel Resection in Crohn"s Disease", 《ACTA MED SCAND》 *
ELLIOT M. BERRY ET AL.: "Carcinoid myopathy and treatment with cyproheptadine (Periactin)", 《GUT》 *
IVAR LONNROTH ET AL.: "Chlorpromazine Reverses Diarrhea in Piglets Caused by Enterotoxigenic Escherichia coli", 《INFECTION AND IMMUNITY》 *
JOSEPH D. FONDACARO ET AL.: "Cecectomized Rat: A Model of Experimental Secretory Diarrhea in Conscious Animals", 《JOURNAL OF PHARMACOLOGICAL METHODS》 *
PETER W.STACPOOLE ET AL.: "Combination H1 and H2 Receptor Antagonist Therapy in Diabetic Autonomic Neuropathy", 《SOURTHEN MEDICAL JOURNAL》 *
RENE THONHOFER ET AL.: "Mastocytic enterocolitis as a rare cause of chronic diarrhea in a patient with rheumatoid arthritis", 《WIEN KLIN WOCHENSCHR》 *
SHRIRAM JAKATE ET AL.: "Mastocytic Enterocolitis Increased Mucosal Mast Cells in Chronic Intractable Diarrhea", 《ACRH PATHOL LAB MED》 *
SPIEGEL DR ET AL.: "Treatment of irritable bowel syndrome with comorbid anxiety symptoms with mirtazapine", 《CLINICAL NEUROPHARMACOLOGY》 *

Also Published As

Publication number Publication date
HK1247557B (en) 2020-07-03
KR20150139535A (ko) 2015-12-11
IL273377B1 (en) 2023-06-01
IL241372A0 (en) 2015-11-30
JP6790140B2 (ja) 2020-11-25
US20190038619A1 (en) 2019-02-07
KR101884506B1 (ko) 2018-08-01
HK1213205A1 (en) 2016-06-30
US11058681B2 (en) 2021-07-13
WO2014152420A3 (en) 2014-11-20
IL256300B (en) 2020-04-30
HUE035201T2 (hu) 2018-05-02
ZA201708539B (en) 2019-05-29
AU2019201412A1 (en) 2019-03-21
JP2021046400A (ja) 2021-03-25
WO2014152420A2 (en) 2014-09-25
US20140275116A1 (en) 2014-09-18
JP2018135340A (ja) 2018-08-30
BR122017004716A2 (pt) 2019-07-30
KR20180088514A (ko) 2018-08-03
EP3269364A1 (en) 2018-01-17
US10034875B2 (en) 2018-07-31
CA2906005A1 (en) 2014-09-25
EP3269364B1 (en) 2019-05-29
DK2968205T3 (da) 2017-11-27
IL241372B (en) 2018-06-28
RU2015143475A (ru) 2017-04-20
PT2968205T (pt) 2018-01-05
BR112015022513A2 (pt) 2017-07-18
KR102449977B1 (ko) 2022-09-30
JP2016513692A (ja) 2016-05-16
EP3581205A2 (en) 2019-12-18
ES2655505T3 (es) 2018-02-20
EP2968205A2 (en) 2016-01-20
US20170049770A1 (en) 2017-02-23
MX366329B (es) 2019-07-05
US20220047583A1 (en) 2022-02-17
AU2014239878A1 (en) 2015-10-15
MX2015011885A (es) 2016-05-16
AU2014239878B2 (en) 2017-08-24
US9717726B2 (en) 2017-08-01
CN105324112A (zh) 2016-02-10
ES2743604T3 (es) 2020-02-20
JP2019089796A (ja) 2019-06-13
AU2017251701B2 (en) 2019-03-14
IL256300A (en) 2018-02-28
JP6473254B2 (ja) 2019-02-20
EP3581205A3 (en) 2020-03-25
JP6313417B2 (ja) 2018-04-18
IL273377B2 (en) 2023-10-01
IL273377A (en) 2020-05-31
KR20210021606A (ko) 2021-02-26
MX350814B (es) 2017-09-21
CN105324112B (zh) 2018-08-17
PL2968205T3 (pl) 2018-03-30
AU2017251701A1 (en) 2017-11-09
CA2906005C (en) 2021-12-28
KR20200100211A (ko) 2020-08-25
MY175326A (en) 2020-06-19
EP2968205B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
JP6790140B2 (ja) 下痢を治療するための製品及び方法
HK1247557A1 (en) Product and method for treating diarrhea
US20250325540A1 (en) Low dose product and method for treating diarrhea
Comella et al. A tailored regimen including capecitabine and oxaliplatin for treating elderly patients with metastatic colorectal carcinoma: Southern Italy Cooperative Oncology Group trial 0108
HK1213205B (en) Product and method for treating diarrhea
JP2026511098A (ja) 糖尿病性胃不全麻痺を治療するための方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181207

WD01 Invention patent application deemed withdrawn after publication